Targinine Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Targinine Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: CONDITIONAL GO
Decision memo
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
The central underwriting question is whether Targinine can convert its Small molecule drug profile and NOSs biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Targinine (query alias: Targinine) |
|---|---|
| Modality / target | Small molecule drug; NOSs; NOS inhibitors |
| Highest global status | Phase 2 |
| Originator | Astellas Pharma, Inc. |
| Active developers | Houston Methodist Research Institute, The Methodist Hospital Research Institute |
The MCP disease footprint includes HER2-negative breast cancer, Metastatic breast cancer, Triple Negative Breast Cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07629622 | Not Applicable | Completed | 30 | Primary endpoint not disclosed in English source |
| NCT05660083 | Phase 2 | Recruiting | 36 | Primary endpoint not disclosed in English source |
| NCT03625349 | Not Applicable | Active, not recruiting | 130 | Primary endpoint not disclosed in English source |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Phase Ib Trial of L-NMMA in Combination With Pembrolizumab in Patients With Melanoma, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma, Urothelial Carcinoma, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Primary Mediastinal Large B-cell Lymphoma, Renal Cell Carcinoma, Small Cell Lung Cancer, Microsatellite Instability-High/Mismatch Repair Deficient Cancer, or for the Treatment of Adult Patients With Unresectable or Metastatic Tumor Mutational Burden-High Solid Tumors
Phase 1; n=12; evaluation: Not stated in English source. Reported fields: Other (Not Including Serious) Adverse Events = 0 Pts ; Number of Patients with AE of any grade = 3 Pts
Clinical Phase Ib/II Trial of L-NMMA Plus Taxane Chemotherapy in the Treatment of Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients
Phase 1/2; n=37; evaluation: Not stated in English source. Reported fields: Asses the Maximum Tolerated Dose (MTD) of L-NMMA When Combined With Docetaxel/Amlodipine in the Treatment of Refractory Locally Advanced or Metastatic TNBC Patients, Based on the Number of Dose Limiting Toxicities (DLTs) Per Dose Level. = 20 mg/kg ; CR = 0 Pts
4904 Regimen Intensity and Age Affect Transplant-Related Outcomes after Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell Disease: A STAR Registry Study
Not Applicable; n=352; evaluation: Not stated in English source. Reported fields: OS = 94.4 % (CI, 91.3 - 97.7); GRFS = 69 % (CI, 0.57 - 0.83)
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Targinine addresses HER2-negative breast cancer, Metastatic breast cancer, Triple Negative Breast Cancer. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The MCP screen returned 7 matched transaction record(s) under the scope “target-level comparable: NOSs.” Partner activity is a market-validation signal, but it does not establish net present value.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: NOSs records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2025-07-30 | Orsini Selected as Specialty Pharmacy Partner for PTC Therapeutics’ SEPHIENCE™ (sepiapterin) | Approved | Financial terms not disclosed |
| 2024-09-01 | Yaqrit acquired full global rights, including development and commercial, for OPA in any indication from Mallinckrodt Pharmaceuticals in the second half of 2024. | Phase 3 | Financial terms not disclosed |
| 2023-08-24 | Transaction title not available in English source | Phase 2 | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Composition for generating nitrogen monoxide”. The milestone feed surfaced a patent-application signal described as “Patent source description not available in English”. The milestone feed surfaced a patent-application signal described as “Method of treating a subject suffering from degenerative disc disease using a nitric oxide synthase inhibitor”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.
7. Principal risks and diligence gates
- Therapeutic index and off-target toxicity
- Resistance biology and biomarker-defined patient selection
- Differentiation from established and emerging standards
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
CONDITIONAL GO
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 2026-09-18. Counts and status fields may change as source records update.
